Point-of-Care and Self-administered Biologicals to 2026

self administered biologicals  POC and Self-administered Biologicals  • TDD483K • August 2021 • US$3,850



Led by the proliferation of antibody-based drugs and candidates, biological drugs as a class continue to outpace all other NCEs in development pipelines and clinical trials. This shift away from small molecule drugs is creating opportunities for drug developers, device designers, packagers and – ultimately – pharmaceutical marketers. Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition. The shift in as-supplied packaging from single and multi-use vials to prefilled injection devices will accelerate over the next five years as drug developers move to empower an increasing number of chronically ill patients. The powerful physiological effects of antibodies, hormones and other biological drugs also increase the need for safety and compliance.



POC & Self-administered Biologicals – What You Will Learn

  • What are the market factors that define the point-of-care biologicals delivery market? What factors define the self-administration biologicals market?
  • What are the major factors driving the As Supplied product development decision within drug development organizations?
  • How does the availability of patient support resources influence the prescribing decision for biological drugs?
  • How important are drug developer-formulation technologist relationships in the POC market segment? In the self-administration market segment?
  • In what therapeutic market segments do biologicals compete? What is their market share today? What will it be in 2026? What is their expected growth rate?
  • What are the significant economic, technology, and regulatory factors affecting the selection criteria for point-of-care and self-administered biological drugs?


Summary of Contents

Biological Drug Product Factors

   As-supplied Containers

   Formulation Factors

   Biological Drug Delivery Ecosystem

   Technology Factors

Competitive Landscape

Global Injection Device Manufacturing

   North America



Therapeutic Biologicals – As Supplied Segments

   Point of Care


Market Presence of Leading Biologicals Suppliers

Drug Class Analysis


   Fusion Proteins

   Granulocyte – Colony Stimulating Factor (G-CSF)


   Immune Modulators


   Recombinant Proteins

Biological Drug Profiles

Market Data and Forecasts

Delivery Devices for Biological Drugs